HIV/HCV合并感染晚期纤维化/肝硬化患者经直接抗病毒药物清除HCV后的临床结局与预后因素
研究纳入西班牙2014至2017年经直接抗病毒药物获得持续病毒学应答的1300例HIV/HCV合并感染患者,中位随访40.9个月。非肝脏非AIDS相关事件是各肝病阶段的主要死因;代偿期晚期慢性肝病患者中,基线肝硬度测量及治疗后基于肝硬度的模型有助于评估失代偿和肝细胞癌风险。
要点
- 非肝脏非AIDS相关事件是晚期纤维化/肝硬化合并感染患者DAA治愈后的主要死因。
- 失代偿年发生率:晚期纤维化0、代偿期肝硬化1.01/100人年、失代偿期肝硬化8.35/100人年。
- 肝细胞癌年发生率:晚期纤维化0.34/100人年、代偿期肝硬化0.73/100人年、失代偿期肝硬化1.92/100人年。
核心结论
- 非肝脏非AIDS相关事件是HIV/HCV合并感染晚期纤维化/肝硬化患者经DAA治愈后的主要发病和死亡原因。
- 代偿期晚期慢性肝病患者中,基线肝硬度测量和治疗后基于肝硬度的模型有助于评估失代偿和肝细胞癌风险。
研究设计与样本
- 西班牙2014至2017年经DAA获得持续病毒学应答的HIV/HCV合并感染患者共1300例。
- 1145例为代偿期晚期慢性肝病(384例晚期纤维化、761例代偿期肝硬化),155例为失代偿期肝硬化;中位随访40.9个月。
主要发现
- 共发生85例死亡,其中61例为非肝脏非AIDS相关原因,为各肝病阶段首要死因。
- 失代偿年发生率(95%CI):晚期纤维化0,代偿期肝硬化1.01(0.68-1.51)/100人年,失代偿期肝硬化8.35(6.05-11.53)/100人年。
- 肝细胞癌年发生率(95%CI):晚期纤维化0.34(0.13-0.91)/100人年,代偿期肝硬化0.73(0.45-1.18)/100人年,失代偿期肝硬化1.92(1.00-3.70)/100人年。
- 代偿期晚期慢性肝病患者失代偿的预后因素包括血清白蛋白、肝硬度测量(LSM)和纤维化4指数。
- 该人群中,LSM及基于LSM的治疗后风险分层模型对失代偿和肝细胞癌显示预测能力。
临床怎么用
- 代偿期晚期慢性肝病患者中,基线LSM和治疗后基于LSM的模型有助于评估失代偿和肝细胞癌风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: We assessed long-term clinical outcomes and prognostic factors for liver disease progression after sustained viral response with direct-acting antivirals in patients coinfected with HIV/HCV with advanced fibrosis or cirrhosis. APPROACH AND RESULTS: A total of 1300 patients who achieved sustained viral response with direct-acting antivirals from 2014 to 2017 in Spain were included: 1145 with compensated advanced chronic liver disease (384 advanced fibrosis and 761 compensated cirrhosis) and 155 with decompensated cirrhosis. The median follow-up was 40.9 months. Overall, 85 deaths occurred, 61 due to non-liver non-AIDS-related causes that were the leading cause of death across all stages of liver disease. The incidence (95% CI) of decompensation per 100 person-years (py) was 0 in patients with advanced fibrosis, 1.01 (0.68-1.51) in patients with compensated cirrhosis, and 8.35 (6.05-11.53) in patients with decompensated cirrhosis. The incidence (95% CI) of HCC per 100 py was 0.34 (0.13-0.91) in patients with advanced fibrosis, 0.73 (0.45-1.18) in patients with compensated cirrhosis, and 1.92 (1.00-3.70) per 100 py in patients with decompensated cirrhosis. Prognostic factors for decompensation in patients with compensated advanced chronic liver disease included serum albumin, liver stiffness measurement (LSM), and fibrosis 4. In this population, LSM and LSM-based posttreatment risk stratification models showed their predictive ability for decompensation and HCC. CONCLUSIONS: Non-liver non-AIDS-related events were the leading causes of morbidity and mortality after direct-acting antiviral cure among coinfected patients with advanced fibrosis/cirrhosis. Among those with compensated advanced chronic liver disease, baseline LSM and posttreatment LSM-based models helped to assess decompensation and HCC risk.
引用
- Berenguer J, Aldámiz-Echevarría T, Hontañón V, et al. Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis. Hepatology. 2024. PMID: 38452004. doi:10.1097/HEP.0000000000000838
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。